Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects

Results from the non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR), diabete de type 2, nephropathie et genetique (DIAB2NEPHROGENE), and survie, diabete de type 2 et genetique (SURDIAGENE) studies

Samy Hadjadj, Frédéric Fumeron, Ronan Roussel, Pierre Jean Saulnier, Pharmd Yves Gallois, Amos Ankotche, Florence Travert, Charbel Abi Khalil, Aurélie Miot, Francois Alhenc-Gelas, Michel Lievre, Michel Marre

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

OBJECTIVE - We tested whether determination of the ACE insertion/deletion polymorphism is useful for renal and cardiovascular prognoses of type 2 diabetic subjects. RESEARCH DESIGN AND METHODS - The French participants (3,126 of 4,912) in the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) trial were studied for their prognosis over 4 years according to their ACE insertion/deletion polymorphism. We used two cohorts of French type 2 diabetic patients for replication: a 3-year follow-up study (n = 917; Survie, Diabete de type 2 et Genetique [SURDIAGENE] study) and a case-control study on diabetic nephropathy (n = 1,277;Diabete de type 2, Nephropathie et Genetique [DIAB2NEPHROGENE] study). We investigated the effect of the insertion/deletion polymorphism on the primary outcome in the DIABHYCAR trial (defined as the first of the following events to occur: cardiovascular death, nonfatal myocardial infarction, stroke, heart failure leading to hospital admission, or end-stage renal failure) and its components. RESULTS - In DIABHYCAR, the primary outcome and most of its components were not affected by the ACE insertion/deletion genotype. Only renal outcome was favored by the I allele (P = 0.03). The risk of myocardial infarction was not affected by ACE genotype, but the probability of fatal outcome increased with the number of D alleles (P < 0.03). In SURDIAGENE, the association between the ACE I allele andrenal outcome was not replicated. In DIAB2NEPHROGENE, no association was found with nephropathy.CONCLUSIONS - We were not able to demonstrate the manifest usefulness of the ACE insertion/deletion polymorphism for the prognosis of type 2 diabetic subjects.

Original languageEnglish
Pages (from-to)1847-1852
Number of pages6
JournalDiabetes Care
Volume31
Issue number9
DOIs
Publication statusPublished - Sep 2008
Externally publishedYes

Fingerprint

Ramipril
Proteinuria
Alleles
Hypertension
Myocardial Infarction
Genotype
Genes
Kidney
Fatal Outcome
Diabetic Nephropathies
Chronic Kidney Failure
Case-Control Studies
Research Design
Heart Failure
Stroke

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialised Nursing

Cite this

Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects : Results from the non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR), diabete de type 2, nephropathie et genetique (DIAB2NEPHROGENE), and survie, diabete de type 2 et genetique (SURDIAGENE) studies. / Hadjadj, Samy; Fumeron, Frédéric; Roussel, Ronan; Saulnier, Pierre Jean; Gallois, Pharmd Yves; Ankotche, Amos; Travert, Florence; Abi Khalil, Charbel; Miot, Aurélie; Alhenc-Gelas, Francois; Lievre, Michel; Marre, Michel.

In: Diabetes Care, Vol. 31, No. 9, 09.2008, p. 1847-1852.

Research output: Contribution to journalArticle

@article{2df57dfd21a941f7a65ce0dbe3744430,
title = "Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: Results from the non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR), diabete de type 2, nephropathie et genetique (DIAB2NEPHROGENE), and survie, diabete de type 2 et genetique (SURDIAGENE) studies",
abstract = "OBJECTIVE - We tested whether determination of the ACE insertion/deletion polymorphism is useful for renal and cardiovascular prognoses of type 2 diabetic subjects. RESEARCH DESIGN AND METHODS - The French participants (3,126 of 4,912) in the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) trial were studied for their prognosis over 4 years according to their ACE insertion/deletion polymorphism. We used two cohorts of French type 2 diabetic patients for replication: a 3-year follow-up study (n = 917; Survie, Diabete de type 2 et Genetique [SURDIAGENE] study) and a case-control study on diabetic nephropathy (n = 1,277;Diabete de type 2, Nephropathie et Genetique [DIAB2NEPHROGENE] study). We investigated the effect of the insertion/deletion polymorphism on the primary outcome in the DIABHYCAR trial (defined as the first of the following events to occur: cardiovascular death, nonfatal myocardial infarction, stroke, heart failure leading to hospital admission, or end-stage renal failure) and its components. RESULTS - In DIABHYCAR, the primary outcome and most of its components were not affected by the ACE insertion/deletion genotype. Only renal outcome was favored by the I allele (P = 0.03). The risk of myocardial infarction was not affected by ACE genotype, but the probability of fatal outcome increased with the number of D alleles (P < 0.03). In SURDIAGENE, the association between the ACE I allele andrenal outcome was not replicated. In DIAB2NEPHROGENE, no association was found with nephropathy.CONCLUSIONS - We were not able to demonstrate the manifest usefulness of the ACE insertion/deletion polymorphism for the prognosis of type 2 diabetic subjects.",
author = "Samy Hadjadj and Fr{\'e}d{\'e}ric Fumeron and Ronan Roussel and Saulnier, {Pierre Jean} and Gallois, {Pharmd Yves} and Amos Ankotche and Florence Travert and {Abi Khalil}, Charbel and Aur{\'e}lie Miot and Francois Alhenc-Gelas and Michel Lievre and Michel Marre",
year = "2008",
month = "9",
doi = "10.2337/dc07-2079",
language = "English",
volume = "31",
pages = "1847--1852",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "9",

}

TY - JOUR

T1 - Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects

T2 - Results from the non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR), diabete de type 2, nephropathie et genetique (DIAB2NEPHROGENE), and survie, diabete de type 2 et genetique (SURDIAGENE) studies

AU - Hadjadj, Samy

AU - Fumeron, Frédéric

AU - Roussel, Ronan

AU - Saulnier, Pierre Jean

AU - Gallois, Pharmd Yves

AU - Ankotche, Amos

AU - Travert, Florence

AU - Abi Khalil, Charbel

AU - Miot, Aurélie

AU - Alhenc-Gelas, Francois

AU - Lievre, Michel

AU - Marre, Michel

PY - 2008/9

Y1 - 2008/9

N2 - OBJECTIVE - We tested whether determination of the ACE insertion/deletion polymorphism is useful for renal and cardiovascular prognoses of type 2 diabetic subjects. RESEARCH DESIGN AND METHODS - The French participants (3,126 of 4,912) in the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) trial were studied for their prognosis over 4 years according to their ACE insertion/deletion polymorphism. We used two cohorts of French type 2 diabetic patients for replication: a 3-year follow-up study (n = 917; Survie, Diabete de type 2 et Genetique [SURDIAGENE] study) and a case-control study on diabetic nephropathy (n = 1,277;Diabete de type 2, Nephropathie et Genetique [DIAB2NEPHROGENE] study). We investigated the effect of the insertion/deletion polymorphism on the primary outcome in the DIABHYCAR trial (defined as the first of the following events to occur: cardiovascular death, nonfatal myocardial infarction, stroke, heart failure leading to hospital admission, or end-stage renal failure) and its components. RESULTS - In DIABHYCAR, the primary outcome and most of its components were not affected by the ACE insertion/deletion genotype. Only renal outcome was favored by the I allele (P = 0.03). The risk of myocardial infarction was not affected by ACE genotype, but the probability of fatal outcome increased with the number of D alleles (P < 0.03). In SURDIAGENE, the association between the ACE I allele andrenal outcome was not replicated. In DIAB2NEPHROGENE, no association was found with nephropathy.CONCLUSIONS - We were not able to demonstrate the manifest usefulness of the ACE insertion/deletion polymorphism for the prognosis of type 2 diabetic subjects.

AB - OBJECTIVE - We tested whether determination of the ACE insertion/deletion polymorphism is useful for renal and cardiovascular prognoses of type 2 diabetic subjects. RESEARCH DESIGN AND METHODS - The French participants (3,126 of 4,912) in the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) trial were studied for their prognosis over 4 years according to their ACE insertion/deletion polymorphism. We used two cohorts of French type 2 diabetic patients for replication: a 3-year follow-up study (n = 917; Survie, Diabete de type 2 et Genetique [SURDIAGENE] study) and a case-control study on diabetic nephropathy (n = 1,277;Diabete de type 2, Nephropathie et Genetique [DIAB2NEPHROGENE] study). We investigated the effect of the insertion/deletion polymorphism on the primary outcome in the DIABHYCAR trial (defined as the first of the following events to occur: cardiovascular death, nonfatal myocardial infarction, stroke, heart failure leading to hospital admission, or end-stage renal failure) and its components. RESULTS - In DIABHYCAR, the primary outcome and most of its components were not affected by the ACE insertion/deletion genotype. Only renal outcome was favored by the I allele (P = 0.03). The risk of myocardial infarction was not affected by ACE genotype, but the probability of fatal outcome increased with the number of D alleles (P < 0.03). In SURDIAGENE, the association between the ACE I allele andrenal outcome was not replicated. In DIAB2NEPHROGENE, no association was found with nephropathy.CONCLUSIONS - We were not able to demonstrate the manifest usefulness of the ACE insertion/deletion polymorphism for the prognosis of type 2 diabetic subjects.

UR - http://www.scopus.com/inward/record.url?scp=56149092278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56149092278&partnerID=8YFLogxK

U2 - 10.2337/dc07-2079

DO - 10.2337/dc07-2079

M3 - Article

VL - 31

SP - 1847

EP - 1852

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 9

ER -